HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats

Bin Zhang, Eric J. West, Ken C. Van, Gene G Gurkoff, Jia Zhou, Xiu Mei Zhang, Alan P. Kozikowski, Bruce G Lyeth

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Traumatic brain injury (TBI) produces a rapid and robust inflammatory response in the brain characterized in part by activation of microglia. A novel histone deacetylase (HDAC) inhibitor, 4-dimethylamino-N-[5-(2-mercaptoacetylamino)pentyl]benzamide (DMA-PB), was administered (0, 0.25, 2.5, 25 mg/kg) systemically immediately after lateral fluid percussion TBI in rats. Hippocampal CA2/3 tissue was processed for acetyl-histone H3 immunolocalization, OX-42 immunolocalization (for microglia), and Fluoro-Jade B histofluorescence (for degenerating neurons) at 24 h after injury. Vehicle-treated TBI rats exhibited a significant reduction in acetyl-histone H3 immunostaining in the ipsilateral CA2/3 hippocampus compared to the sham TBI group (p < 0.05). The reduction in acetyl-histone H3 immunostaining was attenuated by each of the DMA-PB dosage treatment groups. Vehicle-treated TBI rats exhibited a high density of phagocytic microglia in the ipsilateral CA2/3 hippocampus compared to sham TBI in which none were observed. All doses of DMA-PB significantly reduced the density of phagocytic microglia (p < 0.05). There was a trend for DMA-PB to reduce the number of degenerating neurons in the ipsilateral CA2/3 hippocampus (p = 0.076). We conclude that the HDAC inhibitor DMA-PB is a potential novel therapeutic for inhibiting neuroinflammation associated with TBI.

Original languageEnglish (US)
Pages (from-to)181-191
Number of pages11
JournalBrain Research
Volume1226
DOIs
StatePublished - Aug 21 2008

Fingerprint

Histone Deacetylase Inhibitors
Microglia
Acetylation
Histones
Hippocampus
Percussion
Neurons
Traumatic Brain Injury
Wounds and Injuries
Brain

Keywords

  • Fluid percussion
  • Histone deacetylase
  • Inflammation
  • Microglia
  • Traumatic brain injury

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Developmental Biology
  • Molecular Biology

Cite this

HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. / Zhang, Bin; West, Eric J.; Van, Ken C.; Gurkoff, Gene G; Zhou, Jia; Zhang, Xiu Mei; Kozikowski, Alan P.; Lyeth, Bruce G.

In: Brain Research, Vol. 1226, 21.08.2008, p. 181-191.

Research output: Contribution to journalArticle

Zhang, Bin ; West, Eric J. ; Van, Ken C. ; Gurkoff, Gene G ; Zhou, Jia ; Zhang, Xiu Mei ; Kozikowski, Alan P. ; Lyeth, Bruce G. / HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. In: Brain Research. 2008 ; Vol. 1226. pp. 181-191.
@article{da647d437b6f4d43bf3e6ac8e323f52a,
title = "HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats",
abstract = "Traumatic brain injury (TBI) produces a rapid and robust inflammatory response in the brain characterized in part by activation of microglia. A novel histone deacetylase (HDAC) inhibitor, 4-dimethylamino-N-[5-(2-mercaptoacetylamino)pentyl]benzamide (DMA-PB), was administered (0, 0.25, 2.5, 25 mg/kg) systemically immediately after lateral fluid percussion TBI in rats. Hippocampal CA2/3 tissue was processed for acetyl-histone H3 immunolocalization, OX-42 immunolocalization (for microglia), and Fluoro-Jade B histofluorescence (for degenerating neurons) at 24 h after injury. Vehicle-treated TBI rats exhibited a significant reduction in acetyl-histone H3 immunostaining in the ipsilateral CA2/3 hippocampus compared to the sham TBI group (p < 0.05). The reduction in acetyl-histone H3 immunostaining was attenuated by each of the DMA-PB dosage treatment groups. Vehicle-treated TBI rats exhibited a high density of phagocytic microglia in the ipsilateral CA2/3 hippocampus compared to sham TBI in which none were observed. All doses of DMA-PB significantly reduced the density of phagocytic microglia (p < 0.05). There was a trend for DMA-PB to reduce the number of degenerating neurons in the ipsilateral CA2/3 hippocampus (p = 0.076). We conclude that the HDAC inhibitor DMA-PB is a potential novel therapeutic for inhibiting neuroinflammation associated with TBI.",
keywords = "Fluid percussion, Histone deacetylase, Inflammation, Microglia, Traumatic brain injury",
author = "Bin Zhang and West, {Eric J.} and Van, {Ken C.} and Gurkoff, {Gene G} and Jia Zhou and Zhang, {Xiu Mei} and Kozikowski, {Alan P.} and Lyeth, {Bruce G}",
year = "2008",
month = "8",
day = "21",
doi = "10.1016/j.brainres.2008.05.085",
language = "English (US)",
volume = "1226",
pages = "181--191",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats

AU - Zhang, Bin

AU - West, Eric J.

AU - Van, Ken C.

AU - Gurkoff, Gene G

AU - Zhou, Jia

AU - Zhang, Xiu Mei

AU - Kozikowski, Alan P.

AU - Lyeth, Bruce G

PY - 2008/8/21

Y1 - 2008/8/21

N2 - Traumatic brain injury (TBI) produces a rapid and robust inflammatory response in the brain characterized in part by activation of microglia. A novel histone deacetylase (HDAC) inhibitor, 4-dimethylamino-N-[5-(2-mercaptoacetylamino)pentyl]benzamide (DMA-PB), was administered (0, 0.25, 2.5, 25 mg/kg) systemically immediately after lateral fluid percussion TBI in rats. Hippocampal CA2/3 tissue was processed for acetyl-histone H3 immunolocalization, OX-42 immunolocalization (for microglia), and Fluoro-Jade B histofluorescence (for degenerating neurons) at 24 h after injury. Vehicle-treated TBI rats exhibited a significant reduction in acetyl-histone H3 immunostaining in the ipsilateral CA2/3 hippocampus compared to the sham TBI group (p < 0.05). The reduction in acetyl-histone H3 immunostaining was attenuated by each of the DMA-PB dosage treatment groups. Vehicle-treated TBI rats exhibited a high density of phagocytic microglia in the ipsilateral CA2/3 hippocampus compared to sham TBI in which none were observed. All doses of DMA-PB significantly reduced the density of phagocytic microglia (p < 0.05). There was a trend for DMA-PB to reduce the number of degenerating neurons in the ipsilateral CA2/3 hippocampus (p = 0.076). We conclude that the HDAC inhibitor DMA-PB is a potential novel therapeutic for inhibiting neuroinflammation associated with TBI.

AB - Traumatic brain injury (TBI) produces a rapid and robust inflammatory response in the brain characterized in part by activation of microglia. A novel histone deacetylase (HDAC) inhibitor, 4-dimethylamino-N-[5-(2-mercaptoacetylamino)pentyl]benzamide (DMA-PB), was administered (0, 0.25, 2.5, 25 mg/kg) systemically immediately after lateral fluid percussion TBI in rats. Hippocampal CA2/3 tissue was processed for acetyl-histone H3 immunolocalization, OX-42 immunolocalization (for microglia), and Fluoro-Jade B histofluorescence (for degenerating neurons) at 24 h after injury. Vehicle-treated TBI rats exhibited a significant reduction in acetyl-histone H3 immunostaining in the ipsilateral CA2/3 hippocampus compared to the sham TBI group (p < 0.05). The reduction in acetyl-histone H3 immunostaining was attenuated by each of the DMA-PB dosage treatment groups. Vehicle-treated TBI rats exhibited a high density of phagocytic microglia in the ipsilateral CA2/3 hippocampus compared to sham TBI in which none were observed. All doses of DMA-PB significantly reduced the density of phagocytic microglia (p < 0.05). There was a trend for DMA-PB to reduce the number of degenerating neurons in the ipsilateral CA2/3 hippocampus (p = 0.076). We conclude that the HDAC inhibitor DMA-PB is a potential novel therapeutic for inhibiting neuroinflammation associated with TBI.

KW - Fluid percussion

KW - Histone deacetylase

KW - Inflammation

KW - Microglia

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=48849095167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48849095167&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2008.05.085

DO - 10.1016/j.brainres.2008.05.085

M3 - Article

C2 - 18582446

AN - SCOPUS:48849095167

VL - 1226

SP - 181

EP - 191

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -